Drug rash: Difference between revisions
| Line 17: | Line 17: | ||
=== Table of Severe Drug Reactions === | === Table of Severe Drug Reactions === | ||
[[File:Characteristics-of-4-main-ddx-DRESS.jpg|900px]] | [[File:Characteristics-of-4-main-ddx-DRESS.jpg|900px]] | ||
{| {{table}} | |||
| align="center" style="background:#f0f0f0;"|'''Charateristic''' | |||
| align="center" style="background:#f0f0f0;"|'''DRESS''' | |||
| align="center" style="background:#f0f0f0;"|'''SJS/TEN''' | |||
| align="center" style="background:#f0f0f0;"|'''AGEP''' | |||
| align="center" style="background:#f0f0f0;"|'''Erythroderma''' | |||
|- | |||
| Onset of eruption||2-6 weeks||1-3 weeks||48 hours||1-3 weeks | |||
|- | |||
| Duration of eruption (weeks)||Several||1-3||<1||Several | |||
|- | |||
| Fever||+++||+++||+++||+++ | |||
|- | |||
| Mucocutaneous features||Facial edema, morbilliform eruption, pustules, exfoliative dermattiis, tense bullae, possible target lesions||Bullae, atypical target lesions, mucocutaneous erosions||Facial edema, pustules, tense bullae, possible target lesions, possibl emucosal involvement||Erythematous plaques and edema affecting >90% of total skin surface with or without diffuse exfoliation | |||
|- | |||
| Histological pattern of skin||Perivascular lymphocytcic infiltrate||Epidermal necrosis||Subcorneal pustules||Nonspecific, unless reflecting Sezary syndrome or other lymphoma | |||
|- | |||
| Lymph node enlargement||+++||-||+||+ | |||
|- | |||
| Lymph node histology||Lymphoid hyperplasia||-||-||No, unless reflecting Sezary syndrome or other malignancy | |||
|- | |||
| Hepatitis||+++||++||++||- | |||
|- | |||
| Other organ involvement||Interstitial nephritis, pneumonitis, myocarditis, and thydoiditis||Tubular nephritis and tracheobronical necrosis||Possible||Possible | |||
|- | |||
| Neutrophils||Elevated||Decreased||Very elevated||Elevated | |||
|- | |||
| Eosinophils||Very elevated||No change||Elevated||Elevated | |||
|- | |||
| Atypical lymphocytes||+||-||-||+ | |||
|- | |||
| Mortality (%)||10||5-35||5||5-15 | |||
|} | |||
==Evaluation== | ==Evaluation== | ||
Revision as of 18:54, 17 December 2019
Background
ABCs of Drug Rashes
- Acute generalized exanthematous pustulosis (AGEP)
- Bullous disease, drug induced
- Captopril (ACE-inhibitor) induced angioedema
- Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome
- SJS/TEN
Clinical Features
- Sudden, usually morbilliform, often starts on face & trunk & spreads
- More polymorphous than viral exanthem
Differential Diagnosis
Erythematous rash
- Positive Nikolsky’s sign
- Febrile
- Staphylococcal scalded skin syndrome (children)
- Toxic epidermal necrolysis/SJS (adults)
- Afebrile
- Febrile
- Negative Nikolsky’s sign
- Febrile
- Afebrile
Table of Severe Drug Reactions
| Charateristic | DRESS | SJS/TEN | AGEP | Erythroderma |
| Onset of eruption | 2-6 weeks | 1-3 weeks | 48 hours | 1-3 weeks |
| Duration of eruption (weeks) | Several | 1-3 | <1 | Several |
| Fever | +++ | +++ | +++ | +++ |
| Mucocutaneous features | Facial edema, morbilliform eruption, pustules, exfoliative dermattiis, tense bullae, possible target lesions | Bullae, atypical target lesions, mucocutaneous erosions | Facial edema, pustules, tense bullae, possible target lesions, possibl emucosal involvement | Erythematous plaques and edema affecting >90% of total skin surface with or without diffuse exfoliation |
| Histological pattern of skin | Perivascular lymphocytcic infiltrate | Epidermal necrosis | Subcorneal pustules | Nonspecific, unless reflecting Sezary syndrome or other lymphoma |
| Lymph node enlargement | +++ | - | + | + |
| Lymph node histology | Lymphoid hyperplasia | - | - | No, unless reflecting Sezary syndrome or other malignancy |
| Hepatitis | +++ | ++ | ++ | - |
| Other organ involvement | Interstitial nephritis, pneumonitis, myocarditis, and thydoiditis | Tubular nephritis and tracheobronical necrosis | Possible | Possible |
| Neutrophils | Elevated | Decreased | Very elevated | Elevated |
| Eosinophils | Very elevated | No change | Elevated | Elevated |
| Atypical lymphocytes | + | - | - | + |
| Mortality (%) | 10 | 5-35 | 5 | 5-15 |
Evaluation
- Typically a clinical diagnosis
Management
- Discontinue offending agent
- Supportive
- Topical steroids may help relieve pruritus
Disposition
- If no signs of anaphylaxis or significant sloughing, consider outpatient management
